SNARK, a novel downstream molecule of EBV latent membrane protein 1, is associated with resistance to cancer cell death

被引：17
作者：
Kim, Joo Hyun [2 ]
Kim, Won Seog [2 ,3 ]
Park, Chaehwa [1 ,2 ]
机构：
[1] Sungkyunkwan Univ, Sch Med, Ctr Canc, Samsung Med Ctr, Seoul 135710, South Korea
[2] Sungkyunkwan Univ, Sch Med, Biomed Res Inst, Samsung Med Ctr, Seoul 135710, South Korea
[3] Sungkyunkwan Univ, Sch Med, Dept Med, Samsung Med Ctr, Seoul 135710, South Korea
来源：
LEUKEMIA & LYMPHOMA | 2008年 / 49卷 / 07期
关键词：
LMP1; SNARK; Epstein-Barr virus; microarray; cell lines and animal models; neoplasia; drug resistance; lymphoma and Hodgkin disease;
D O I：
10.1080/10428190802087454
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
To investigate the effect of Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) on human cancer cells, we sought to identify and analyse potential target genes that were differentially expressed in the presence and absence of LMP1. LMP1 upregulated the expression of SNARK compared with the empty vector transfected control cells, which was confirmed by reverse-transcription polymerase chain reaction. Cytotoxicity assay showed that SNARK expression increased drug resistance in response to doxorubicin (P=0.0009), whereas knockdown of SNARK by siRNA (siSNARK) effectively inhibited LMP-1-mediated increase of cell survival (P=0.0131). The expression of anti-apoptotic genes such as BCL6 and BIRC2 was increased by SNARK, and knockdown of these genes decreased SNARK-mediated increase of cell survival. The associations of SNARK, BCL6, and BIRC2 and the presence of EBV were also observed in T-cell lymphoma cell lines, NKL and HANK-1. These results suggest that SNARK is a downstream cellular target of LMP1 in malignant cells and can be a novel candidate for therapeutic intervention of EBV-associated cancer.
引用
收藏
页码：1392 / 1398
页数：7
相关论文
共 25 条
[1]   Detection of Epstein-Barr virus in invasive breast cancers [J].
Bonnet, M ;
Guinebretiere, JM ;
Kremmer, E ;
Grunewald, V ;
Benhamou, E ;
Contesso, G ;
Joab, I .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (16) :1376-1381
[2]   Mechanism of action of a novel latent membrane protein-1 dominant negative [J].
Brennan, P ;
Floettmann, JE ;
Mehl, A ;
Jones, M ;
Rowe, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (02) :1195-1203
[3]   Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappa B control [J].
Chu, ZL ;
McKinsey, TA ;
Liu, L ;
Gentry, JJ ;
Malim, MH ;
Ballard, DW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (19) :10057-10062
[4]   EXPRESSION OF EPSTEIN-BARR VIRUS-ENCODED PROTEINS IN NASOPHARYNGEAL CARCINOMA [J].
FAHRAEUS, R ;
FU, HL ;
ERNBERG, I ;
FINKE, J ;
ROWE, M ;
KLEIN, G ;
FALK, K ;
NILSSON, E ;
YADAV, M ;
BUSSON, P ;
TURSZ, T ;
KALLIN, B .
INTERNATIONAL JOURNAL OF CANCER, 1988, 42 (03) :329-338
[5]   Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule [J].
Gires, O ;
ZimberStrobl, U ;
Gonnella, R ;
Ueffing, M ;
Marschall, G ;
Zeidler, R ;
Pich, D ;
Hammerschmidt, W .
EMBO JOURNAL, 1997, 16 (20) :6131-6140
[6]  
Griffin B E, 2000, Mutat Res, V462, P395, DOI 10.1016/S1383-5742(00)00028-4
[7]   The AMP-activated/SNF1 protein kinase subfamily: Metabolic sensors of the eukaryotic cell? [J].
Hardie, DG ;
Carling, D ;
Carlson, M .
ANNUAL REVIEW OF BIOCHEMISTRY, 1998, 67 :821-855
[8]  
HARDIE DG, 1996, FEBS LETT, V246, P113
[9]   Establishment of an IL-2-dependent cell line derived from 'nasal-type' NK/T-cell lymphoma of CD2+, sCD3-, CD3ε+, CD56+ phenotype and associated with the Epstein-Barr virus [J].
Kagami, Y ;
Nakamura, S ;
Suzuki, R ;
Iida, S ;
Yatabe, Y ;
Okada, Y ;
Kobayashi, T ;
Tsurumi, T ;
Seto, M ;
Ogura, M ;
Taguchi, O ;
Morishima, Y .
BRITISH JOURNAL OF HAEMATOLOGY, 1998, 103 (03) :669-677
[10]   Critical roles of AMP-activated protein kinase in constitutive tolerance of cancer cells to nutrient deprivation and tumor formation [J].
Kato, K ;
Ogura, T ;
Kishimoto, A ;
Minegishi, Y ;
Nakajima, N ;
Miyazaki, M ;
Esumi, H .
ONCOGENE, 2002, 21 (39) :6082-6090
123